Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 11-18

  Yu, Hsin Hui ^a   Chen, Pau Chung ^b   Yang, Yao Hsu ^a   Wang, Li Chieh ^a   Lee, Jyh Hong ^a   Lin, Yu Tsan ^a   Chiang, Bor Luen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular disease; Epidemiology; Mortality; Statin; Systemic lupus erythematosus

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; END STAGE RENAL DISEASE; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; CEREBROVASCULAR DISORDERS; COMPLICATION; DOSE RESPONSE; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; REGRESSION ANALYSIS; REPRODUCIBILITY; TAIWAN;

ADULT; ANTI-INFLAMMATORY AGENTS; CEREBROVASCULAR DISORDERS; COHORT STUDIES; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOLOGIC FACTORS; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TAIWAN;

EID: 84940785004     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.030     Document Type: Article

References (43)

1. Bruce I.N. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best. Pract. Res. Clin. Rheumatol. 2005, 19:823-838.
2. Symmons D.P., Gabriel S.E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol. 2011, 7:399-408.
3. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., D'Agostino R.B., Kuller L.H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 1997, 145:408-415.
4. Sherer Y., Zinger H., Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity 2010, 43:98-102.
5. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., Cote R., Grover S.A., Fortin P.R., Clarke A.E., Senecal J.L. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44:2331-2337.
6. van Leuven S.I., Franssen R., Kastelein J.J., Levi M., Stroes E.S., Tak P.P. Systemic inflammation as a risk factor for atherothrombosis. Rheumatol. (Oxf.) 2008, 47:3-7.
7. Norby G.E., Holme I., Fellstrom B., Jardine A., Cole E., Abedini S., Holdaas H., Assessment of Lescol in Renal Transplantation Study Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum. 2009, 60:1060-1064.
8. Westerweel P.E., Luyten R.K., Koomans H.A., Derksen R.H., Verhaar M.C. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 2007, 56:1384-1396.
9. van Leuven S.I., Mendez-Fernandez Y.V., Stroes E.S., Tak P.P., Major A.S. Statin therapy in lupus-mediated atherogenesis: two birds with one stone?. Ann. Rheum. Dis. 2011, 70:245-248.
10. Nikpour M., Urowitz M.B., Ibanez D., Harvey P.J., Gladman D.D. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res. Ther. 2011, 13:R156.
11. Sandborg C., Ardoin S.P., Schanberg L. Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2008, 4:258-265.
12. Pasterkamp G., van Lammeren G.W. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev. Cardiovasc Ther. 2010, 8:1235-1237.
13. Tu H., Li Q., Xiang S., Jiang H., Mao Y., Shou Z., Chen J. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis 2012, 222:29-33.
14. Petri M.A., Kiani A.N., Post W., Christopher-Stine L., Magder L.S. Lupus atherosclerosis prevention study (LAPS). Ann. Rheum. Dis. 2011, 70:760-765.
15. Mok C.C., Wong C.K., To C.H., Lai J.P., Lam C.S. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. (Hoboken) 2011, 63:875-883.
16. Plazak W., Gryga K., Dziedzic H., Tomkiewicz-Pajak L., Konieczynska M., Podolec P., Musial J. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res. Ther. 2011, 13:R117.
17. Schanberg L.E., Sandborg C., Barnhart H.X., Ardoin S.P., Yow E., Evans G.W., Mieszkalski K.L., Ilowite N.T., Eberhard A., Imundo L.F., Kimura Y., von Scheven E., Silverman E., Bowyer S.L., Punaro M., Singer N.G., Sherry D.D., McCurdy D., Klein-Gitelman M., Wallace C., Silver R., Wagner-Weiner L., Higgins G.C., Brunner H.I., Jung L., Soep J.B., Reed A.M., Provenzale J., Thompson S.D. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012, 64:285-296.
18. Tsan Y.T., Lee C.H., Wang J.D., Chen P.C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol. 2012, 30:623-630.
19. Lin J.A., Liao C.C., Lee Y.J., Wu C.H., Huang W.Q., Chen T.L. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann. Rheum. Dis. 2014, 73:1646-1651.
20. Cheng C.L., Kao Y.H., Lin S.J., Lee C.H., Lai M.L. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol. Drug Saf. 2011, 20:236-242.
21. Lin C.C., Lai M.S., Syu C.Y., Chang S.C., Tseng F.Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J. Formos. Med. Assoc. 2005, 104:157-163.
22. Cheng C.-L., Lee C.-H., Chen P.-S., Li Y.-H., Lin S.-J., Yang Y.-H.K. Validation of acute myocardial infarction cases in the national Health Insurance Research Database in Taiwan. J. Epidemiol. 2014, 24:500-507.
23. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725.
24. Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., Bacon P., Bombardieri S., Hanly J., Hay E., Isenberg D., Jones J., Kalunian K., Maddison P., Nived O., Petri M., Richter M., Sanchez-Guerrero J., Snaith M., Sturfelt G., Symmons D., Zoma A. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996, 39:363-369.
25. van der Meij E., Koning G.G., Vriens P.W., Peeters M.F., Meijer C.A., Kortekaas K.E., Dalman R.L., van Bockel J.H., Hanemaaijer R., Kooistra T., Kleemann R., Lindeman J.H. A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One 2013, 8:e53882.
26. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
27. Doria A., Gatto M., Zen M., Iaccarino L., Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun. Rev. 2014, 13:770-777.
28. Gladman D.D., Urowitz M.B., Rahman P., Ibanez D., Tam L.S. Accrual of organ damage over time in patients with systemic lupus erythematosus. J. Rheumatol. 2003, 30:1955-1959.
29. Mok C.C., Kwok R.C., Yip P.S. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013, 65:2154-2160.
30. Upadhyay A. Statins in chronic kidney disease: what do meta-analyses tell us?. Clin. Exp. Nephrol. 2014, 18:278-281.
31. Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 2006, 6:358-370.
32. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000, 6:1399-1402.
33. Waehre T., Yndestad A., Smith C., Haug T., Tunheim S.H., Gullestad L., Froland S.S., Semb A.G., Aukrust P., Damas J.K. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004, 109:1966-1972.
34. Jury E.C., Isenberg D.A., Mauri C., Ehrenstein M.R. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol. 2006, 177:7416-7422.
35. Ruiz-Limon P., Barbarroja N., Perez-Sanchez C., Aguirre M.A., Bertolaccini M.L., Khamashta M.A., Rodriguez-Ariza A., Almaden Y., Segui P., Khraiwesh H., Gonzalez-Reyes J.A., Villalba J.M., Collantes-Estevez E., Cuadrado M.J., Lopez-Pedrera C. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann. Rheum. Dis. 2015, 74:1450-1458.
36. Fatemi A., Moosavi M., Sayedbonakdar Z., Farajzadegan Z., Kazemi M., Smiley A. Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial. Clin. Rheumatol. 2014, 33:1273-1278.
37. Willis R., Seif A.M., McGwin G., Martinez-Martinez L.A., Gonzalez E.B., Doan E., Dang N., Papalardo E., Liu J., Vila L.M., Reveille J.D., Alarcon G.S., Pierangeli S.S. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort. Clin. Exp. Rheumatol. 2014, 32:162-167.
38. Fox R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthritis Rheum. 1993, 23:82-91.
39. Wallace D.J., Gudsoorkar V.S., Weisman M.H., Venuturupalli S.R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 2012, 8:522-533.
40. Fessler B.J., Alarcon G.S., McGwin G., Roseman J., Bastian H.M., Friedman A.W., Baethge B.A., Vila L., Reveille J.D. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005, 52:1473-1480.
41. Cairoli E., Rebella M., Danese N., Garra V., Borba E.F. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012, 21:1178-1182.
42. Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014, 384:626-635.
43. Mohassel P., Mammen A.L. The spectrum of statin myopathy. Curr. Opin. Rheumatol. 2013, 25:747-752.